ONC Stock Overview
Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Oncimmune Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.26 |
| 52 Week High | UK£0.45 |
| 52 Week Low | UK£0.13 |
| Beta | 1.12 |
| 1 Month Change | 46.67% |
| 3 Month Change | -1.49% |
| 1 Year Change | -34.81% |
| 3 Year Change | -87.63% |
| 5 Year Change | -71.91% |
| Change since IPO | -80.08% |
Recent News & Updates
Shareholder Returns
| ONC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 25.7% | -0.5% | 0.4% |
| 1Y | -34.8% | -28.5% | -1.0% |
Return vs Industry: ONC underperformed the UK Biotechs industry which returned -28.5% over the past year.
Return vs Market: ONC underperformed the UK Market which returned -1% over the past year.
Price Volatility
| ONC volatility | |
|---|---|
| ONC Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ONC's share price has been volatile over the past 3 months.
Volatility Over Time: ONC's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Martin Gouldstone | www.oncimmune.com |
Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.
Oncimmune Holdings plc Fundamentals Summary
| ONC fundamental statistics | |
|---|---|
| Market cap | UK£19.56m |
| Earnings (TTM) | -UK£6.15m |
| Revenue (TTM) | UK£1.15m |
17.0x
P/S Ratio-3.2x
P/E RatioIs ONC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONC income statement (TTM) | |
|---|---|
| Revenue | UK£1.15m |
| Cost of Revenue | UK£360.00k |
| Gross Profit | UK£792.00k |
| Other Expenses | UK£6.94m |
| Earnings | -UK£6.15m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.083 |
| Gross Margin | 68.75% |
| Net Profit Margin | -533.94% |
| Debt/Equity Ratio | 786.9% |
How did ONC perform over the long term?
See historical performance and comparison